Clinical Trials, Phase I as Topic
"Clinical Trials, Phase I as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.
Descriptor ID |
D017321
|
MeSH Number(s) |
E05.318.760.250.500.200 N05.715.360.775.088.500.200 N06.850.520.450.250.250.200
|
Concept/Terms |
Microdosing Trials, Human- Microdosing Trials, Human
- Human Microdosing Trial
- Microdosing Trial, Human
- Trial, Human Microdosing
- Trials, Human Microdosing
- Human Microdosing Trials
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase I as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase I as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase I as Topic" by people in this website by year, and whether "Clinical Trials, Phase I as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 4 | 4 |
1995 | 0 | 2 | 2 |
1996 | 1 | 1 | 2 |
1997 | 0 | 4 | 4 |
1998 | 1 | 1 | 2 |
1999 | 1 | 3 | 4 |
2000 | 0 | 4 | 4 |
2001 | 1 | 10 | 11 |
2002 | 0 | 5 | 5 |
2003 | 2 | 6 | 8 |
2004 | 1 | 5 | 6 |
2005 | 2 | 5 | 7 |
2006 | 2 | 7 | 9 |
2007 | 5 | 5 | 10 |
2008 | 3 | 2 | 5 |
2009 | 9 | 3 | 12 |
2010 | 6 | 6 | 12 |
2011 | 4 | 10 | 14 |
2012 | 5 | 9 | 14 |
2013 | 6 | 7 | 13 |
2014 | 4 | 9 | 13 |
2015 | 6 | 7 | 13 |
2016 | 3 | 15 | 18 |
2017 | 1 | 4 | 5 |
2018 | 6 | 4 | 10 |
2019 | 4 | 8 | 12 |
2020 | 2 | 10 | 12 |
2021 | 0 | 8 | 8 |
2022 | 1 | 8 | 9 |
2023 | 1 | 1 | 2 |
2024 | 0 | 7 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase I as Topic" by people in Profiles.
-
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
-
TGF-? trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance. J Immunother Cancer. 2024 Oct 26; 12(10).
-
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clin Trials. 2024 Jun; 21(3):267-272.
-
Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates. Sci Transl Med. 2024 Apr 03; 16(741):eadl2055.
-
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Apr; 125:102720.
-
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics. 2024 Jan 29; 80(1).
-
Statistical and practical considerations in planning and conduct of dose-optimization trials. Clin Trials. 2024 Jun; 21(3):273-286.
-
Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clin Trials. 2024 Jun; 21(3):287-297.
-
Tisotumab vedotin in recurrent or metastatic cervical cancer. Curr Probl Cancer. 2023 06; 47(3):100952.
-
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clin Cancer Res. 2022 12 15; 28(24):5272-5279.